百合股份: 威海百合生物技术股份有限公司2025年半年度报告摘要

Company Overview - Weihai Baihe Biotechnology Co., Ltd. reported total assets of approximately 1.87 billion RMB at the end of the reporting period, reflecting a 3.07% increase compared to the previous year [1] - The company's operating income for the reporting period was approximately 420.35 million RMB, which is a 2.06% increase from 411.88 million RMB in the same period last year [1] - The total profit for the period was approximately 82.36 million RMB, showing a decrease of 13.38% compared to 95.08 million RMB in the previous year [1] - The net profit attributable to shareholders of the listed company was approximately 69.64 million RMB, down 13.68% from 80.67 million RMB in the same period last year [1] Shareholder Information - The largest shareholder, Liu Xinli, holds 40.94% of the shares, amounting to 26,198,803 shares [2] - Other significant shareholders include Liu Zhaomin with 3.03% (1,936,742 shares) and Liu Luzeng with 2.67% (1,710,730 shares) [2] - Liu Zhaomin is identified as the actual controller of the company, and there are familial connections among the major shareholders [2]